scholarly journals A review of telmisartan in the treatment of hypertension: blood pressure control in the early morning hours

2006 ◽  
Vol 2 (3) ◽  
pp. 195-201 ◽  
Author(s):  
Philippe Gosse
2012 ◽  
Vol 25 (1) ◽  
pp. 54-59 ◽  
Author(s):  
H. A. W. v. Onzenoort ◽  
W. J. Verberk ◽  
A. A. Kroon ◽  
A. G. H. Kessels ◽  
C. Neef ◽  
...  

2010 ◽  
Vol 6 (2) ◽  
pp. 18
Author(s):  
Markus P Schlaich ◽  
Murray D Esler ◽  
◽  

Non-optimal blood pressure is the leading cause of death globally, and each year is responsible for seven million deaths. Current therapeutic strategies for hypertension are mainly based on lifestyle interventions and pharmacological approaches, but rates of blood pressure control remain unsatisfactory and additional options are required. In this context, novel device-based approaches specifically targeting the sympathetic nervous system as a major player in blood pressure control have recently been tested clinically with promising results. Device-based approaches may provide additional and more effective treatment of hypertension and its adverse consequences in the future.


2011 ◽  
Vol 3 (1) ◽  
pp. 37
Author(s):  
Markus P Schlaich ◽  
Murray D Esler ◽  
◽  

Non-optimal blood pressure is the leading cause of cardiovascular-related death worldwide, and each year is responsible for seven million deaths. Current therapeutic strategies for hypertension are mainly based on lifestyle interventions and pharmacological approaches, but rates of blood pressure control remain unsatisfactory and additional options are required. In this context, novel device-based approaches specifically targeting the sympathetic nervous system as a major player in blood pressure control have recently been tested clinically with promising results. Device-based approaches may provide additional and more effective treatment of hypertension and its adverse consequences in the future.


1976 ◽  
Vol 51 (s3) ◽  
pp. 597s-599s
Author(s):  
H. Åberg ◽  
H. Hedstrand

1. In a health examination survey of 2322 men, aged 49–50 years, the prevalence of hypertension was 7·5%. All men with a supine diastolic blood pressure ≥ 105 mmHg were invited to a hypertension clinic. 2. Two years' treatment in eighty-six men achieved a blood pressure reduction of 31/16 mmHg, which was maintained for a 4 years period and considered satisfactory in 80% of the subjects. Propranolol was used in more than 80% of the cases. 3. The study indicates that it is possible to obtain acceptable blood pressure control in the community.


2009 ◽  
Vol 1 ◽  
pp. CMT.S1991
Author(s):  
S Lam ◽  
S Saxena ◽  
LO Macina ◽  
PE Lester

Hypertension can lead to significant morbidity and mortality, and requires lifestyle modifications with or without drug therapy to achieve target blood pressure control. Various classes of anti-hypertensive medications are available to healthcare providers. Choice of medications is based not only on efficacy but also tolerability and cost. Aliskiren is the first drug of a new class of agents known as renin inhibitors. It is approved by the U.S. Food and Drug Administration (FDA) as monotherapy or combination therapy with other antihypertensive agents to optimize blood pressure control. Its efficacy in blood pressure reduction is superior to placebo and comparable to angiotensin receptor blockers, hydrochlorothiazide, angiotensin-converting-enzyme inhibitors and atenolol. It also offers additional blood pressure reduction when used in combination of other agents. Recently, a study demonstrated its efficacy and safety in the elderly, and a study suggested its renoprotective effects in patient who were already taking losartan. More clinical studies are awaited to assess its potential for cardiovascular disease risk reduction. This paper reviews the pharmacology, efficacy and safety of aliskiren for the treatment of hypertension.


Sign in / Sign up

Export Citation Format

Share Document